Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
Journal
Hepatology international
Journal Volume
15
Journal Issue
6
Pages
1421
Date Issued
2021-12
Author(s)
Teng, Wei
Chang, Ting-Tsung
Yang, Hwai-I
Peng, Cheng-Yuan
Su, Chien-Wei
Hu, Tsung-Hui
Yu, Ming-Lung
Wu, Jaw-Ching
Abstract
ALT ≥ 80 U/L and HBV DNA ≥ 2000 IU/ml are treatment criteria of APASL guidelines for chronic hepatitis B (CHB) patients. The need of antiviral therapy for patients in gray zone (ALT < 80 U/L or HBV DNA < 2000 IU/ml) is controversial. This study aimed to develop a scoring system to predict hepatocellular carcinoma (HCC) and evaluate the benefit of antiviral therapy in these patients.
Subjects
Antiviral therapy; Benefits; Family history; Gray zone; Hepatitis B virus; Hepatocellular carcinoma; Noncirrhosis; prediction; Risk score; Treatment guidelines
Publisher
SPRINGER
Type
journal article